sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
acuggagcaccguuaaggaca | 352 | JP7516613B2 | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,240,716 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ccccuguagguugcuuaaaag | 382 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ccccuguagguugcuuaaaag | 382 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ccccuguagguugcuuaaaag | 72 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ccccuguagguugcuuaaaag | 72 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
aaacaugcugucccuaauaaa | 266 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
aaacaugcugucccuaauaaa | 266 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
aaacaugcugucccuaauaaa | 473 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
aaacaugcugucccuaauaaa | 473 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcuuaaaagggacaguuuucu | 95 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
gcuuaaaagggacaguuuucu | 95 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggauccuugcugcugggcucu | 236 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggauccuugcugcugggcucu | 236 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggauccuugcugcugggcucu | 443 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggauccuugcugcugggcucu | 443 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggauccuugcugcugggcucu | 237 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggauccuugcugcugggcucu | 237 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggauccuugcugcugggcucu | 444 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggauccuugcugcugggcucu | 444 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agagcccagcagcaaggaucccu | 289 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agagcccagcagcaaggaucccu | 289 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agagcccagcagcaaggaucccu | 598 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agagcccagcagcaaggaucccu | 598 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agagcccagcagcaaggaucccu | 288 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agagcccagcagcaaggaucccu | 288 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agagcccagcagcaaggaucccu | 599 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
agagcccagcagcaaggaucccu | 599 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuguccuuaacggugcuccagua | 148 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuguccuuaacggugcuccagua | 148 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuguccuuaacggugcuccagua | 147 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuguccuuaacggugcuccagua | 147 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuguccuuaacggugcuccagua | 510 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuguccuuaacggugcuccagua | 510 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuguccuuaacggugcuccagua | 509 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
uuguccuuaacggugcuccagua | 509 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acaagccuccaagacggucca | 247 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acaagccuccaagacggucca | 247 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acaagccuccaagacggucca | 246 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acaagccuccaagacggucca | 246 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acaagccuccaagacggucca | 454 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acaagccuccaagacggucca | 454 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acaagccuccaagacggucca | 453 | JP2024147603A | アポリポタンパク質C3(APOC3)iRNA組成物およびその使用方法 | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
acaagccuccaagacggucca | 453 | JP2024147603A | APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | 20,241,016 | 3 | [
"JP",
"US",
"AU",
"HK",
"CN",
"EP",
"CA",
"WO"
] | null |
ggaucaacgacgagaucga | 1707 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
ggaucaacgacgagaucga | 1020 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
ggaggcacaauuagaccag | 136 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
ggaggcacaauuagaccag | 1508 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uccucugaauaguuuaaau | 140 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uccucugaauaguuuaaau | 898 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uccucugaauaguuuaaau | 1390 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
agucgacuaggugggaaua | 1686 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
agucgacuaggugggaaua | 1039 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
caggacggcaauaaauuag | 1372 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
caggacggcaauaaauuag | 889 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
caggacggcaauaaauuag | 74 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
augauggcuuaaaucgaac | 1432 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
augauggcuuaaaucgaac | 98 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
cacagaguuuguaguaaau | 39 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
cacagaguuuguaguaaau | 1459 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
guacagucccagcacauuu | 1375 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
guacagucccagcacauuu | 880 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
guacagucccagcacauuu | 20 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
cccggcgggcgucgcgcuu | 1057 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
caauaaggcucaugcacaa | 1017 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
caauaaggcucaugcacaa | 1701 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
aaaagguucuggguagcag | 1418 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
aaaagguucuggguagcag | 89 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
cgggugucuaggaggcaca | 1434 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
cgggugucuaggaggcaca | 99 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
gauccuccgggcuuccuug | 1718 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
gauccuccgggcuuccuug | 1055 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
augugauaauuguucuaaa | 141 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
augugauaauuguucuaaa | 1516 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
gcagggacaagcgcgacgc | 1035 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uucucagucaugcacucac | 1463 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uucucagucaugcacucac | 41 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uauccuaguuccauucuug | 46 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uauccuaguuccauucuug | 1473 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
gugagugcaugacugagaa | 1464 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
gugagugcaugacugagaa | 114 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uccauucuuggucaaguuu | 1505 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uccauucuuggucaaguuu | 62 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
acaauaaggcucaugcaca | 1028 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
cucucuuucaauugcagau | 44 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
cucucuuucaauugcagau | 1469 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
aaaugugcugggacuguac | 1376 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
aaaugugcugggacuguac | 93 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
aaaugugcugggacuguac | 891 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
ccaagaauggaacuaggau | 1452 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
ccaagaauggaacuaggau | 108 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
accucucgaaccaauugug | 1063 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
acaagagggacuguauuuc | 1383 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
acaagagggacuguauuuc | 884 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
aaguacagucccagcacau | 72 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
aaguacagucccagcacau | 1523 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uuuagaacaauuaucacau | 68 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
uuuagaacaauuaucacau | 1515 | US20220348915A1 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | 20,221,103 | 3 | [
"US"
] | null |
caguuucuugagaucugcuga | 2939 | WO2022072447A1 | SNCA IRNA compositions and methods of use thereof for treating or preventing SNCA-associated neurodegenerative diseases | 20,220,407 | 224 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caguuucuugagaucugcuga | 2939 | WO2022072447A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,220,407 | 224 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
caguuucuugagaucugcuga | 2148 | WO2022072447A1 | SNCA IRNA compositions and methods of use thereof for treating or preventing SNCA-associated neurodegenerative diseases | 20,220,407 | 224 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.